Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23 mars 2023 07h12 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
22 mars 2023 17h23 HE
|
Cidara Therapeutics, Inc.
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – –...
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
07 mars 2023 16h15 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
07 mars 2023 16h01 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
03 mars 2023 09h14 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
02 mars 2023 16h14 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model
01 mars 2023 07h00 HE
|
Cidara Therapeutics, Inc.
A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model when compared to placeboCD388 was generally...
Cidara to Present at ESMO Targeted Anticancer Therapies Congress
28 févr. 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
14 févr. 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
01 févr. 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO and SHANGHAI, China, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the...